Bacil Pharma share price
BSE: 524516Pharmaceuticals & BiotechnologySmall Cap
Bacil Pharma Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1994
Last close ₹18.81up ₹0.41 (2.23%)
Share price at the BSE close on 30 Oct 2026. Previous close ₹18.40.
30 Oct: open ₹18.50, high ₹18.99, low ₹18.40
52-week range of traded prices to 30 Oct 2026
₹10.65Low, 26 Aug 2026₹61.80High, 10 Apr 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹27 Cr3,172nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed. Price to book: how it is worked out
- 1.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −0.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. Taken from the consolidated balance sheet, the company and its subsidiaries together; the P/E is on the company's own results until four consolidated quarters are filed.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,126
Results
Standalone; ₹ crore.Bacil Pharma quarterly results
Quarter to Sep 2026
- Revenue
- ₹0.00 Cr
- Net profit
- ₹0.15 Cr
Revenue by quarter
Net profit by quarter, a loss in red
- Net profit
- Loss
Back to profit in the quarter to Sep 2026, ₹0.15 CrA loss in 2 of the 8 quarters shown
The quarters either side of a change of basis do not compare. From the quarter to Sep 2026, the company reports a discontinued business.
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | −0.06 | 0.02 | 0.67 | 0.01 | 0.04 | 0.62 | −0.02 | 0.15 |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. Under it, revenue in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.00 CrYear to Mar 2025: ₹0.00 Cr
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹1.56 Crup 284.83%
Revenue by year
Peak revenue ₹0.27 Cr, year to Mar 2018; lowest ₹0.00 Cr, year to Mar 2019
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 8 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.17 | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 0.00 | −3.75 | −0.34 | −0.32 | −0.24 | −3.86 | −0.10 | −0.06 | 0.40 | 1.56 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary | −1.2% | −1,368.6% | – | – | – | – | – | – | – | – |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement. Dividend yield is not shown: no dividend in the years on record.Bacil Pharma PE ratio and valuation
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 3% of 868 trading days over the last 5 years.
LowestHighest
Its median3.32Industry median2.89
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +12.3% | +62.2% | −30.8% | 0.0% |
| 3 years | +105.7% | – | – | 0.0% |
| 5 years | +72.6% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 1 year is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Bacil Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Bacil Pharma in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.Healthcare companies
Bacil Pharma is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Jfl Life SciencesJFLLIFE | 32 | 4.77 | 0.70 | – | – | 15.9% | 15.9% | 0.00% |
 Gujarat Terce LaboratoriesGUJTERC | 32 | 15.35 | 3.29 | −7.2% | – | 25.8% | 25.8% | 0.00% |
 Medi CapsMEDICAPQ | 31 | – | 0.28 | −42.9% | – | −1.5% | −8.7% | 0.00% |
 Goldline PharmaceuticalGLPL | 30 | 7.28 | 2.10 | – | – | 28.9% | – | 0.00% |
 Walpar NutritionsWALPAR | 23 | 9.49 | 1.24 | +9.8% | −42.7% | 14.0% | – | 0.00% |
 Lasa SupergenericsLASA | 23 | – | 0.47 | −95.2% | – | −24.8% | −24.8% | 0.00% |
 Welcure Drugs & PharmaceuticalsWELCURE | 22 | – | – | – | – | – | – | 0.00% |
 Ishita Drugs & IndustriesISHITADR | 22 | 31.03 | 1.89 | −28.6% | −31.0% | 6.3% | 5.3% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Bacil Pharma announcements
Oct 2026
14 Oct · Results
8 Oct · Management
5 Oct · Board meeting
Meeting on 14 Oct 2026: quarterly results
Sep 2026
Bacil Pharma share price by year
Each calendar year to 2025.Bacil Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 35.64 | −34.4% | 53.26 | 28.09 |
| 2024 | 54.34 | +751.7% | 62.56 | 6.50 |
| 2023 | 6.38 | −32.1% | 9.72 | 4.68 |
| 2022 | 9.40 | +31.5% | 9.55 | 3.67 |
| 2021 | 7.15 | +51.5% | 8.84 | 3.12 |
| 2020 | 4.72 | +137.2% | 6.01 | 1.57 |
| 2019 | 1.99 | −13.5% | 2.40 | 1.90 |
| 2018 | 2.30 | −61.6% | 5.70 | 2.30 |
| 2017 | 5.99 | −38.2% | 10.25 | 5.32 |
| 2016 | 9.70 | +79.0% | 10.18 | 3.32 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2019 is from its first session, 4 Feb 2019.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 29 Oct 2026 | 19.75 | 20.27 | 18.40 | 18.40 | 18.44 | 29,650 |
| 28 Oct 2026 | 20.29 | 20.29 | 18.38 | 19.36 | 19.16 | 12,111 |
| 27 Oct 2026 | 18.12 | 19.92 | 18.12 | 19.34 | 18.15 | 28,465 |
| 26 Oct 2026 | 19.85 | 20.56 | 18.99 | 19.07 | 19.03 | 14,907 |
| 23 Oct 2026 | 21.34 | 21.34 | 19.42 | 19.98 | 20.00 | 5,940 |
| 22 Oct 2026 | 21.09 | 21.09 | 20.04 | 20.44 | 20.39 | 2,062 |
| 21 Oct 2026 | 19.83 | 21.29 | 19.33 | 21.09 | 19.39 | 22,102 |
| 19 Oct 2026 | 21.41 | 21.41 | 20.34 | 20.34 | 20.42 | 259 |
| 16 Oct 2026 | 20.86 | 21.95 | 20.86 | 21.41 | 20.96 | 1,204 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 524516
- ISIN
- INE711D01018
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.bacilpharma.com
- CIN
- L24200MH1987PLC043427
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1987
- Registered office
- 71, Laxmi Building, Sir P M Road, Fort, Mumbai 400001, Maharashtra
- Share registrar
- Bigshare Services Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments